期刊
LUNG CANCER
卷 92, 期 -, 页码 19-21出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.lungcan.2015.11.023
关键词
Crizotinib; Ceritinib; ALK F1245C; Acquired anaplastic lymphoma kinase resistance mutation; Comprehensive genomic profiling; ALK-positive NSCLC; Next generation sequencing
The emergence of acquired anaplastic lymphoma kinase (ALK) resistant mutations is a common molecular mechanism underpinning disease progression during crizotinib treatment of ALIC-positive (ALK+) non small cell lung cancer (NSCLC) patients. Identifying acquired resistance mutations in ALK is paramount for tailoring future therapy with second generation ALK inhibitors and beyond. Comprehensive genomic profiling using hybrid-capture next generation sequencing has been successful in identifying acquired ALK resistance mutations. Here we described the emergence of an ALK F1245C mutation in an advanced ALK+ NSCLC patient (EML4-ALK variant 3a/b) who developed slow disease progression after a durable response to crizotinib. The patient was eventually switched to ceritinib with on-going clinical response. This is the first patient report that ALK F1245C is an acquired resistance mutation to crizotinib that can be overcome by ceritinib (C) 2015 Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据